Why the study?
Does baseline platelet reactivity measured by PFA-100 correlate with disease severity and clinical outcomes in patients with non-ST-segment elevation ACS?
Does baseline platelet reactivity measured by PFA-100 correlate with disease severity and clinical outcomes in patients with non-ST-segment elevation ACS?
Enhanced baseline platelet reactivity measured by PFA-100 is associated with NSTEMI and predicts clinical complications in patients with non-ST-segment elevation ACS.
UNLABELLED: The aim of this study was to assess the baseline platelet hyperactivity in patients with acute coronary syndrome (ACS) and correlate it with the disease severity and clinical outcome. PARTICIPANTS AND METHODS: This study was conducted on 60 patients with the first attack of non-ST-segment elevation ACS and 30 healthy controls. Patients were subdivided into 2 groups: group I: 40 patients with non-ST-segment elevation myocardial infarction (NSTEMI) and group II: 20 patients with unstable angina. All the studied patients were subjected to baseline platelet function analysis using platelet function analyzer 100 (PFA-100). RESULTS: Group I patients showed significantly lower PFA-100 closure time (CT) than group II (P = .04) and control group (P = .03). The occurrence of complications in NSTEMI patients was associated with older age, hypertension, and shorter baseline collagen adenosine diphosphate PFA-100 CT (P < .05). CONCLUSION: NSTEMI patients proved to have enhanced platelet function that can be used as a predictor of the outcome.
No takes yet. Share an insight, caveat, or question.
Sedky et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: